ONL Therapeutics
Latest round
- Series D
Last raised
- Sep 2024
Total raised
- $117M
Investors
- 18
About ONL Therapeutics
, ONL Therapeutics, Inc. operates as a provider of retinal therapeutics to clinical researchers and healthcare professionals focusing on vision-threatening retinal diseases. In September 2024, ONL Therapeutics, Inc. The company provides a wide range of biopharmaceutical products, such as ONL1204 Ophthalmic Solution for treating geographic atrophy and open-angle glaucoma, as well as research and development in retinal neuroprotection. Additionally, the firm also provides services such as clinical trials and safety assessments for its therapeutic candidates.
Who invested in ONL Therapeutics
18 investors across 6 rounds
See all investors in ONL Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ONL Therapeutics
Who invested in ONL Therapeutics?
ONL Therapeutics has 18 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ONL Therapeutics raised?
ONL Therapeutics has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did ONL Therapeutics last raise money?
ONL Therapeutics's most recent round on record is a Series D, in Sep 2024.
What does ONL Therapeutics do?
ONL Therapeutics is a biotechnology company.
Where is ONL Therapeutics headquartered?
ONL Therapeutics is headquartered in Ann Arbor, US.
Which VCs invest in companies like ONL Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at ONL Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like ONL Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.